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Abstract
Chronic graft-versus-host disease (cGVHD) is associated with mortality, disability and impaired
quality of life. Understanding the role of comorbidity in patients with cGVHD is important both
for prognostication and potentially for tailoring treatments based on mortality risks. In a
prospective cohort study of patients with cGVHD (n=239), we examined the performance of two
comorbidity scales, the Functional Comorbidity Index (FCI) and the Hematopoietic Cell
Transplantation-specific Comorbidity Index (HCT-CI). Both scales detected a higher number of
comorbidities at cGVHD cohort enrollment than pre-HCT (p<0.001). Higher HCT-CI scores at the
time of cGVHD cohort enrollment were associated with higher non-relapse mortality (HR
1.21:1.04–1.42,p=0.01). For overall mortality, we detected an interaction with platelet count.
Higher HCT-CI scores at enrollment were associated with an increased risk of overall mortality
when the platelet count was less than or equal to 100,000/µl (HR 2.01: 1.20–3.35, p=0.01), but not
when it was greater than 100,000/µl (HR 1.05: 0.90–1.22, p=0.53). Comorbidity scoring may help
better predict survival outcomes in patients with cGVHD. Further studies to understand
vulnerability unrelated to cGVHD activity in this patient population are needed.
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Introduction
Chronic graft-versus-host disease (cGVHD) is associated with significant morbidity and
mortality.1,2 In addition to being a leading cause of late treatment-related deaths among
allogeneic recipients, cGVHD is associated with deficits in quality of life that parallel
systemic autoimmune diseases. The Chronic Graft versus Host Disease Consortium was
established to test the 2005 NIH working group definitions for cGVHD severity,3 and to
determine other prognostic measures that predict overall and disease-free survival, non-
relapse mortality, and functional impairment among patients with cGVHD.4 Early data from
the Consortium have demonstrated prognostic utility of the NIH global cGVHD severity
score at enrollment,5 and the poor prognosis of the “overlap” subtype of cGVHD when both
acute and cGVHD manifestations are present concurrently.6 The prevalence of comorbid
illness in patients with cGVHD, and the influence of comorbidity burden upon subsequent
functional and survival outcomes, have been examined in only a single previous study of
100 patients.7
Previous studies have evaluated the role of co-morbidities present at the time of
transplantation and shown that greater comorbidity burden is associated with higher rates of
non-relapse mortality and inferior overall survival compared to patients who have fewer
comorbidities. The Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-
CI) is an example of a standardized way of measuring comorbidities in a population of
hematopoietic cell transplant (HCT) candidates.8 This scale measures a mixture of pre-
existing diagnoses and organ dysfunction at the time of HCT, assigning weights to different
comorbidities to derive a composite score. This scale has demonstrated prognostic
importance among patients receiving transplants for AML and MDS9 including in RIC
settings,10 for CLL,11 and for NHL and MM.12,13 However, it has not been applied to
patients in the post-transplant setting. The Functional Comorbidity Index (FCI) is a
comorbidity scale that was developed in a population of patients with spine disease and
controls,14 with physical function rather than mortality as an outcome. This index has also
been found to predict future physical function in a population of patients with adult
respiratory distress syndrome 15 and has been used to assess HCT patients with cGVHD.7
The prognostic value of the HCT-CI has not yet been examined in the setting of chronic
GVHD. Chronic GVHD imposes unique physiological and functional vulnerabilities
through the effects of the disease itself and the toxicities of the immunosuppressive
treatments used to manage cGVHD. Knowledge of the contribution that factors such as
comorbidity make to the interpretation of survival outcomes in cGVHD has the potential to
strengthen study design and interpretation. This knowledge may also inform risk assessment
and survival prognostication for newly diagnosed cGVHD patients, which may have direct
utility in the clinic. Thus, we determined whether a measure of comorbidity could provide
prognostic information independent of cGVHD characteristics. There are currently no
validated scales for measuring comorbidity in patients with chronic GVHD, so we used the
HCT-CI and FCI to determine comorbidities at the time of enrollment into the cGVHD
consortium and tested their associations with overall mortality and non-relapse mortality.
Finally, we aimed to evaluate whether these scales supplemented information provided by
the NIH cGVHD Global Severity Scale.
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The cGVHD Consortium began patient accrual in 2007 and has prospectively followed
recipients with cGVHD in a multicenter, observational study. Because previously published
data18 have demonstrated discrepancies in the way that the elements of the HCT-CI are
captured between sites, this analysis was restricted to participants from Fred Hutchinson
Cancer Research Center (FHCRC) where two clinicians performed all the chart reviews in
order to ensure uniformity of comorbidity scoring. The protocol was approved by the
Institutional Review Board at Fred Hutchinson Cancer Research Center, and all subjects
provided informed consent in accordance with the Declaration of Helsinki. Enrolled patients
were allogeneic HCT recipients age 2 or older with cGVHD, diagnosed by the NIH
consensus criteria, requiring systemic immunosuppressive therapy. The cohort includes
patients with either classic cGVHD or overlap syndrome. Cases were classified as incident
(enrollment < 3 months after cGVHD diagnosis) or prevalent (enrollment 3 or more months
after cGVHD diagnosis but < 3 years after HCT). At enrollment and every 6 months
thereafter, physicians and patients report standardized information on cGVHD organ
involvement and symptoms. Incident cases had an additional assessment time point 3
months after enrollment. Chronic GVHD global severity (mild, moderate severe) was
determined from individual organ scoring provided by clinicians using the NIH consensus
scoring.
Comorbidity Grading
A complete list of comorbidities was systematically abstracted from medical records for all
patients at transplant and at the time of cGVHD cohort enrollment based on comprehensive
history and physical exam documentation and available test results. Extracted data included
comorbidities found in the FCI and the HCT-CI. These definitions adhered to the respective
FCI and HCT-CI comorbidity definitions with a few exceptions (e.g. pulmonary dysfunction
was assessed by recent PFTs, as in the HCT-CI definition, although the FCI definition uses a
patient history of ARDS, COPD or emphysema).
An FCI score was calculated for each patient based on work by Groll et al.14 The FCI
measures 18 different comorbidities, though this instrument was developed in part to predict
physical function rather than mortality, and has not been studied extensively within the
transplant setting. In this scale, which includes several comorbidities distinct from the HCT-
CI (such as osteoporosis, visual and hearing impairment, and degenerative disc disease),
each comorbidity is assigned a score of 1 and comorbidities are summed to determine a total
score (theoretical range 0–18).
An HCT-CI was calculated for each patient based on work by Sorror et. al.7 The HCT-CI is
a scale that includes 17 comorbidities and was developed to be used at the time of
transplantation. Comorbidities include prior diagnoses (e.g. prior solid malignancy, cardiac
disease), current diagnoses (e.g. active infection, diabetes, obesity, depression) and ongoing
organ dysfunction (e.g. renal, pulmonary, hepatic). Each comorbidity, if present, is assigned
a weighted score from 1 to 3, and some comorbidities are assigned different scores
according to severity (e.g. moderate pulmonary dysfunction is assigned a 2 and severe
pulmonary dysfunction is assigned a 3). The weighted comorbidities are summed to
determine a total score (theoretical range 0–26).
Statistical Methods
Descriptive characteristics of the cohort are reported. The weights and aggregation
algorithms recommended by the scales’ developers were applied to yield an FCI and an
HCT-CI score at two time points: at the time of transplantation and at the time of enrollment
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into the cohort. Paired t-tests were used to determine whether scores changed between the
two time points. NIH cGVHD global severity scoring at the time of enrollment was
calculated from information reported on the case report forms completed by providers. The
association of the proportion of involved patients for each comorbidity item between pre-
transplant and enrollment was evaluated by McNemar’s test.16 Logistic regression models
were used to test associations between individual comorbidities and HCT-CI quartiles.
For the purposes of model construction, cutpoints were used according to previously
reported prognostic importance (platelet count < 100,000/µl vs ≥ 100,000/µl; Karnofsky
performance score < 80 vs ≥ 80; age at transplantation ≥ 50 vs < 50; months between
transplant and enrollment < 12 vs ≥ 12). Both incident and prevalent cases were included.
The HCT-CI was included in the models with published weights as a continuous variable.
The criteria for scoring liver or lung disease as a comorbidity in the HCT-CI overlap with
organ-specific scoring criteria for these manifestations on the NIH cGVHD severity scale.
Both the HCT-CI and the NIH cGVHD severity scale define the presence and severity of
pulmonary dysfunction by abnormalities of the FEV1 or DLCO, though the cut-points are
different between scales and the NIH scale incorporates the Lung Function Score (a
composite of these two variables). For liver, both the HCT-CI and the NIH cGVHD severity
scale define moderate and severe liver dysfunction by abnormalities of the bilirubin or
transaminases, though again the cut-points are different between the two scales. Because of
the overlap between the HCT-CI and the NIH scale for pulmonary and liver dysfunction, we
also tested a version of the HCT-CI that excluded lung and liver dysfunction in calculating
the HCT-CI score.
Univariate and multivariate Cox regression models were constructed to examine
associations between the comorbidity indices at the time of cohort enrollment and
subsequent survival, adjusting for all known and available risk factors. Models were
constructed with and without the NIH global severity score in order to determine the relative
prognostic importance of the comorbidity scales vs. the NIH global severity score. Overall
survival (OS) was calculated from the time of enrollment, with patients censored at the date
last known alive. Non-relapse mortality (NRM) was defined as death prior to relapse, with
relapse treated as a competing event. The C statistic was calculated for the co-morbidity
scores as a measure of their predictive ability for the outcomes of interest. The C statistic
varies from 0.5–1.0, with 0.5 indicating no predictive ability and higher numbers indicating




Baseline characteristics of the 239 patients included in this analysis are displayed in Table
1a (transplant characteristics) and Table 1b (additional variables at the time enrollment into
the cGVHD cohort). Most recipients had a history of prior acute I-IV GVHD (74%). Global
cGVHD severity by NIH criteria was mild or less in 8%, moderate in 54%, and severe in
38% of recipients. Median follow-up of survivors was 32 months (range 0.6–55.0).
Prevalence of co-morbidities according to the FCI
Table 2 demonstrates the complete Functional Comorbidity Index (FCI) and Hematopoietic
Cell Transplantation-specific Comorbidity Index (HCT-CI), at the assessment points. Three
comorbidities in the FCI (peripheral vascular disease, visual impairment, and hearing
impairment) were not seen at the time of transplantation in any recipients. At the time of
transplantation, comorbidities in the FCI seen in more than 10% of recipients included
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pulmonary disease (61%), upper gastrointestinal disease (31%), obesity (25%) and
depression (22%). At the time of cohort enrollment, 13 comorbidities in the FCI increased in
prevalence. Among these, pulmonary disease (69%), osteopenia/osteoporosis (47%), upper
gastrointestinal disease (52%), depression (24%), and diabetes (17%) were seen in more
than 10% of recipients. The proportions of patients with osteopenia/osteoporosis (p <0.001),
lung dysfunction (p =0.02), neurological disease (p=0.007), diabetes (p <0.001), and upper
gastrointestinal disease (p <0.001) were significantly higher at enrollment than at the time of
transplantation, and the proportion of patients with obesity (p <0.001) was significantly
lower at enrollment than at the time of transplantation. The mean FCI score at the time of
transplantation was 1.8 (range 0–8) and increased to 2.7 (range 0–7) at the time of cohort
enrollment (p<0.001).
Prevalence of co-morbidities according to the HCT-CI
Prevalent comorbidities in the HCT-CI at the time of transplantation included moderate
pulmonary dysfunction (41%), psychiatric disturbance (25%), severe pulmonary dysfunction
(20%), prior solid tumor (13%), and obesity (11%) (Table 2). Eight comorbidities in the
HCT-CI were observed in less than 5% of patients. At the time of enrollment, seven
comorbidities were seen in 10% or more of patients: severe pulmonary dysfunction (38%,
nearly doubling from 20% at the time of transplantation), psychiatric disturbance (29%),
moderate pulmonary dysfunction (31%), mild hepatic dysfunction (23%), diabetes (17%),
infection (13%) and prior solid malignancy (13%). The proportions of patients with diabetes
(p<0.001), mild hepatic dysfunction (p<0.001), infection (p=0.007), and severe pulmonary
dysfunction (p<0.001) were significantly higher at cGVHD cohort enrollment than at the
time of transplantation, and the proportions of patients with obesity (p=0.008), and moderate
pulmonary dysfunction (p=0.03) were significantly lower at enrollment than at the time of
transplantation. The mean HCT-CI weighted score at the time of transplantation was 2.6
(range 0–8) and increased to 3.7 (range 0–12) at the time of cohort enrollment (p<0.001).
Table 3 depicts comorbidities in the HCT-CI at the time of cGVHD cohort enrollment, listed
by quartiles of overall HCT-CI scores (0–2, 3, 4–5, and ≥6). The prevalence and number of
comorbidities increased progressively across the score quartiles. For example, in the lowest
quartile, one comorbidity (moderate pulmonary dysfunction) was seen in more than 20% of
patients, whereas in the highest quartile, 8 comorbidities were seen in more than 20% of
patients, including one (severe pulmonary dysfunction) that was identified in more than half
of patients. The proportion of patients with specific comorbidities increased progressively
across HCT-CI quartiles, including cardiac (p=0.001), inflammatory bowel disease (p=0.04),
diabetes (p=0.001), psychiatric disturbance (p<0.001), mild hepatic dysfunction (p=0.02),
infection (p=0.001), moderate/severe renal (p<0.001), severe pulmonary (p<0.001), prior
solid tumor (p<0.001), and moderate/severe hepatic (p<0.001). Table 4 shows the
prevalence of specific comorbidities in patients with a platelet count of ≥ or < 100,000 at the
time of cohort enrollment. There was a significantly higher prevalence of infection in
patients with a platelet count < 100,000 than in patients with a platelet count ≥100,000 at the
time of enrollment (29% vs 10%, p=0.001).
Overall survival
The FCI at the time of cGVHD cohort enrollment was not predictive of overall survival in
univariate or multivariate analysis (data not shown). Table 5 shows that higher HCT-CI
scores at the time of cGVHD cohort enrollment were predictive for an increased risk of
overall mortality (HR 1.16: 1.02–1.31, p=0.02) as a continuous variable in the multivariate
model. Enrollment in the cGVHD cohort within the first year after transplant was an adverse
prognostic factor (HR 2.38: 1.08–5.24, p=0.03), and lower Karnofsky performance score
(<80) at enrollment was also predictive of subsequent higher risk of overall mortality (HR
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2.32: 1.17–4.59, p=0.02). No other variables were statistically significant in the multivariate
analysis. No interaction effect between HCT-CI and case type was observed (p=0.99), but a
statistically significant interaction of the HCT-CI with platelet count was observed
(p=0.003), such that higher HCT-CI scores were associated with an increased risk of overall
mortality when the platelet count was less than 100,000/µl (HR 2.01: 1.20–3.35, p=0.01),
but not when it was greater than 100,000/µl (HR 1.05: 0.90–1.22, p=0.53). After excluding
NIH global severity score in the model, higher HCT-CI scores were still associated with an
increased risk of overall mortality (HR 1.16: 1.03–1.31, p=0.02).
Non-relapse mortality
The FCI at the time of cGVHD cohort enrollment was not predictive of NRM in univariate
or multivariate analysis (data not shown). Table 6 shows that higher HCT-CI scores at
enrollment were predictive for an increased risk of non-relapse mortality (HR 1.21: 1.04–
1.42, p=0.01) in the multivariate model. No interaction effect was observed between HCT-
CI and case type (p=0.69), nor between HCT-CI and platelet count (p=0.12). After
controlling for HCT-CI at the time of transplantation, higher HCT-CI change scores from
the time of transplantation to cohort enrollment were still associated with an increased risk
of NRM (HR: 1.22: 1.00–1.49, p=0.05).
Common elements in the HCT-CI and NIH cGVHD global severity scoring
The NIH global severity score includes liver and lung dysfunction, which together
substantially determine the maximum global severity score based on a previous Consortium
analysis.5 The HCT-CI also includes pulmonary and hepatic dysfunction, with both given
weights up to 3. Because the NIH global severity score predicts mortality, we sought to
determine whether these scales overlapped significantly with one another, and whether liver
and lung dysfunction were responsible for the prognostic importance of the HCT-CI. We
found that overlap existed between the HCT-CI and the NIH cGVHD severity scales at
enrollment in the scoring of liver (correlation=0.61) and lung (correlation=0.61)
dysfunction. We constructed a multivariate model that excluded the NIH severity score, and
found that the significance of the HCT-CI was not enhanced (HR 1.16, p=0.02), suggesting
that the HCT-CI is an independent predictor. We calculated a version of the HCT-CI that
excluded consideration of pulmonary and liver comorbidities. While this version of the
HCT-CI was significant in univariate analysis (HR 1.19, p=0.02), it was not significant in a
covariate-adjusted model (HR 1.15, p=0.12). It is possible that the lack of significance of
this version of the HCT-CI in the multivariate model may reflect lack of prevalence of the
remaining comorbidities to provide sufficient power for this analysis. We also constructed a
model that included pulmonary and liver comorbidity scores individually, without the HCT-
CI, while controlling for other prognostic factors. In this model, neither pulmonary nor liver
dysfunction was statistically associated with an increased risk of mortality (p=0.17 and
p=0.19, respectively). These results suggest that the influence of the HCT-CI on mortality
outcomes is not predominantly accounted for by pulmonary and liver dysfunction. In its
complete form, the HCT-CI showed fair predictive ability for overall survival (c-statistic
0.63) and non-relapse mortality (c-statistic 0.68) in our cGVHD population.
Discussion
We examined the performance of two approaches to comorbidity assessment in patients with
cGVHD. We found that one, the HCT-CI, predicted the risk of mortality when platelet
counts were less than 100,000/µl but not when the platelet count was over 100,000/µl while
another, the FCI, was not associated with the risk of mortality. These results suggest that
understanding comorbidity burden is important in patients with cGVHD because it has
independent prognostic significance even after adjustment for cGVHD variables but that the
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choice of co-morbidity measurement tool matters. We acknowledge that the prognostic
significance of the HCT-CI is modest, and thus may not in its current construction be the
most ideal measure of comorbidity in this patient population. Additionally, the finding of
significance in patients with platelets less than but not more than 100,000 does not have
intuitively obvious meaning, though the difference in prevalence of infection in these two
groups may suggest one possible explanation.
The HCT-CI was developed and validated for use at the time of transplantation and has not
been examined previously in cGVHD, a condition for which there are no currently validated
comorbidity scales. In our study of people with cGVHD, an HCT-CI captured at the time of
enrollment into the cGVHD cohort predicted the risk of subsequent mortality. Whether
comorbidity burden increases equally in patients with or without cGVHD is not currently
known, and should be examined in future studies to determine the proportion of comorbidity
burden increase that can be attributed to cGVHD.
The HCT-CI places particular weight on substantial, objectively measured pulmonary
dysfunction, a variable that has been identified as prognostically relevant in hematopoietic
cell transplantation17 but can also reflect cGVHD and is part of the calculation of cGVHD
global severity. Liver dysfunction is also part of the global NIH severity score. Our analyses
support the relevance of the HCT-CI independent of the NIH severity score, and suggest that
the totality of the index, and not just commonly abnormal variables such as pulmonary and
liver dysfunction, is prognostically relevant for patients with cGVHD.
Several caveats should be considered in generalizing our study findings. Children, ethnic
and racial minorities are under-represented. Patients with mild cGVHD requiring topical
therapy only were not enrolled in the cohort. The HCT-CI, as previously noted, was not
developed nor validated for a patient population with cGVHD. Additionally, HCT-CI
scoring is complicated, laborious, based on specific laboratory tests for some organs, prone
to inter-observer variability, and requires training to ensure accuracy.18 In our study, two
clinicians did all the chart review to generate the HCT-CI scores. Currently, efforts are
underway to ensure uniformity and consistency of HCT-CI scoring across institutions,
which will allow a multicenter effort investigating the relationship of the comorbidities with
outcomes after cGVHD.
Moving forward, we urge further investigations that could lead to a mechanistic
understanding of physiologic vulnerability in patients with cGVHD. Though the original
HCT-CI appears to be prognostically significant in a cGVHD population, the measure was
not developed for use in this population and the prognostic strength of this measure in
patients with cGVHD is modest. It is likely that additional work to develop and validate a
new “cGVHD-CI” will provide greater prognostic information for the cGVHD population.
One could also explore other measures of dysfunction for prognostic relevance that are not
captured in traditional comorbidity scales. Examples of these include longitudinal patient-
reported outcomes (PROs),19 direct functional assessments such as cardiopulmonary
exercise testing,20 or molecular markers of toxicity and aging21 that might help to measure
vulnerability22 in this patient population. The knowledge derived from improved assessment
of comorbidity can be applied in at least three ways. First, the inclusion of comorbidity
scores can help isolate the effects of cGVHD and its treatment on morbidity and mortality,
separate from the effects of concurrent conditions, thus improving the interpretation of
findings in both observational studies and therapeutic trials. Second, comorbidity assessment
can help tailor cGVHD therapies in order to avoid giving overly toxic therapies to patients
who are unable to tolerate them. Lastly, knowledge of comorbidities may also help in
constructing and targeting supportive care regimens to improve overall outcomes.
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For now, we recommend further studies of comorbidity scoring at the time of cGVHD onset
or at enrollment into a clinical trial in order to improve the prediction of outcomes in this
patient population. We also recommend continued study of whether supportive care
interventions or different cGVHD treatment approaches in low versus high comorbidity
scoring patients might influence outcomes. We hope that studies of this kind will lead to
improved overall survival in this vulnerable patient population.
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Table 1
a. Baseline patient characteristics
Characteristic
Age at transplantation, median years (range) 51.8 (2.7–78.9)
Gender, n (%)
  Female 107 (45)
  Male 132 (55)
White, non-Hispanic, n (%) 207 (87)
Case type, n (%)
  Incident 144 (60)
  Prevalent 95 (40)
Diagnosis, n (%)
  Acute leukemia (AML/ALL) 106 (44)
  Chronic leukemia (CML/CLL) 30 (13)
  MDS 50 (21)
  NHL/HD 29 (12)
  MM 12 (5)
  AA 4 (2)
  Other 8 (3)
Disease stage, n (%)*
  Early 90 (38)
  Intermediate 85 (36)
  Advanced 61 (26)
Donor, n (%)
  HLA-matched related 82 (34)
  HLA-matched URD 114 (48)
  HLA-mismatched 43 (18)
Donor sex, n (%)
  Female into male 62 (26)
  Other 177 (74)
Graft source, n (%)
  Mobilized blood 216 (90)
  Bone marrow 19 (8)
  Cord blood 4 (2)
Conditioning regimen, n (%)
  Myeloablative 141 (59)
  Not myeloablative 98 (41)
b. Additional patient characteristics at time of cGVHD cohort enrollment
Characteristic
Age at enrollment, median y (range) 53.0 (11.0–79.0)
Time from transplant to enrollment, median months (range) 11.9 (3.0–294.2)
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b. Additional patient characteristics at time of cGVHD cohort enrollment
Characteristic
Time from transplant to cGVHD onset, median months (range) 7.3 (1.2–291)
Time from cGVHD onset to enrollment, median months (range) 1.6 (0.0–27.1)
Karnofsky performance status at enrollment, n (%)
  80+ 118 (49)
  <80 71 (30)
  Missing 50 (21)
Platelet count at enrollment, 109/L, n (%)
  <100 45 (19)
  ≥100 192 (81)
Prior acute GVHD, n(%)
  Yes 178 (74)
  No 61 (26)
NIH cGVHD severity score, n (%)
  Mild or less 17 (8)
  Moderate 130 (54)
  Severe 92 (38)
Overlap vs classic cGVHD, n( %)
  Classic 46 (19)
  Overlap 193 (81)
*
Missing data for 3 patients
AML indicates acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myeloid leukemia; CLL, chronic lymphocytic
leukemia; MDS, myelodysplastic syndrome; NHL, non-Hodgkin lymphoma; HD, Hodgkin lymphoma; MM, multiple myeloma; AA, aplastic
anemia; HLA, human leukocyte antigen; and URD, unrelated donor.
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Table 4
Distribution of comorbidities by patients with a platelet count ≥ or < 100,000 at the time of enrollment





Arrhythmia 3 (7%) 7 (4%) 0.36
Cardiac 1 (2%) 11 (6%) 0.33
Inflammatory bowel disease 2 (4%) 2 (1%) 0.11
Diabetes 8 (18%) 33 (17%) 0.92
Cerebrovascular disease 0 (0%) 1 (1%) 0.63
Psychiatric 13 (29%) 55 (29%) 0.97
Mild hepatic 11 (24%) 43 (22%) 0.77
Obesity 1 (2%) 13 (7%) 0.25
Infection 13 (29%) 19 (10%) 0.001
Rheumatologic 1 (2%) 5 (3%) 0.88
Ulcer 1 (2%) 2 (1%) 0.52
Moderate/severe renal 3 (7%) 6 (3%) 0.26
Moderate pulmonary 14 (31%) 60 (31%) 0.99
Severe pulmonary 18 (40%) 73 (38%) 0.81
Prior solid malignancy 7 (16%) 24 (13%) 0.58
Heart valve disease 2 (4%) 1 (1%) 0.03
Moderate/severe hepatic 5 (11%) 20 (10%) 0.89
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